All data considered, the benefit of the therapy, Oxbryta, “no longer outweighs the risk,” Pfizer said in a statement ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

The company said it was withdrawing Oxbryta, a daily pill for patients with the disease, a serious, lifelong condition.

Pfizer is withdrawing all of its sickle cell disease drug, Oxbryta, worldwide because of safety concerns. Pfizer ( PFE) ...

U.S. drugmaker Pfizer said on Wednesday it was withdrawing its sickle cell disease treatment Oxbryta from all markets where ...

Pfizer is pulling its sickle cell disease (SCD) treatment voxelotor (Oxbryta) from global markets after data review showed an ...

The US big pharma company Pfizer has voluntarily withdrawn the oral sickle cell disease treatment Oxbryta from the market and ...

Pfizer Inc. (NYSE:PFE) said the company is voluntarily withdrawing all lots of Oxbryta (voxelotor) for the treatment of ...

Pfizer will voluntarily pull its sickle cell disease (SCD) drug Oxbryta from all markets worldwide, a major blow to a $5.4 ...

The EU's drug watchdog Thursday called for the suspension of approval for Pfizer's medicine to treat sickle cell disease, ...

Based on new safety signals, Pfizer on Wednesday announced that Oxbryta’s overall benefit “no longer outweighs the risk” in ...

European Union suspends Pfizer's Oxbryta for sickle cell disease due to safety concerns, urging doctors to stop use ...